Biotech Daily

Wednesday July 8, 2026

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH DOWN: MEDICAL DEVELOPMENTS UP 6%**
- 4D MEDICAL DOWN 7%

*** RESMED SELLS MATRIXCARE TO FRAZIER FOR $706m**

*** COGSTATE FY26 SALES UP 116% TO $128m**

*** CURVEBEAM $5m PLACEMENT; $1m SHARE PLAN**

*** VITRAFY 'OVERSUBSCRIBED' SHARE PLAN RAISES $2m; TOTAL $32m**

*** NEWCASTLE UNI: 'PLASMA DRESSING - BETTER HEALING'**

*** PROTEOMICS: US GRANTS PROMARKER ENDOMETRIOSIS PATENT**

*** PYC US GRANTS PYC-003, PYC-001, VP-001 EXTENDED PATENTS**

*** OPTHEA TO BE 'CERYVYN THERAPEUTICS' TOMORROW**

*** PATRYS DIRECTOR LEANNE KITE TAKES 6%**

*** PERENNIAL REDUCES TO 7% OF MICRO-X**

*** PRO MEDICUS APPOINTS GARRY SHERRIFF IR HEAD**

MARKET REPORT
The Australian stock market fell 0.21 percent on Wednesday July 8, 2026, with the ASX200 down 18.8 points to 8,785.1 points. Nine of the Biotech Daily Top 40 companies were up, 25 fell, and six traded unchanged. The Big Caps were mixed.

Medical Developments was the best, up 2.5 cents or 6.1 percent to 43.5 cents, with 39,849 shares traded. Aroa, Saluda and Syntara climbed more than four percent; Optiscan and Prescient were up more than three percent; Actinogen and Neuren rose more than two percent; with Clarity, CSL and Pro Medicus up by less than one percent.

4D Medical led the falls, down 32 cents or 7.2 percent to $4.10, with 12.5 million shares traded. Amplia, Prescient and Resonance lost more than six percent; Compumedics, Dimerix and Micro-X were down more than five percent; Artrya, Botanix, Imricor, Imugene, and Lumos fell four percent or more; both Immutep and Racura were down 3.64 percent; Avita, Emvision, Nanosonics, Orthocell and Paradigm shed more than two percent; Cochlear, EBR, Mesoblast and Telix lost one percent or more; with Clinuvel, Polynovo, Resmed and Starpharma down by less than one percent.

RESMED
Resmed says it has an agreement to sell its Matrixcare business for $US490 million ($A706 million) in cash to healthcare private equity firm Frazier Healthcare Partners.
Resmed said the sale to the Seattle, Washington-based Frazier Healthcare was for its Matrixcare and related software, including Healthcare First, Citus and home health and hospice products, but excluded its other software businesses.
The company said Matrixcare provided “software [products] to more than 15,000 providers and supports skilled nursing, senior living and long-term care, life planning communities, and home health and hospice care”.
Resmed said based on preliminary financial results for the year to June 30, 2026, the Matrixcare business was about $US220 million of revenue and $US55 million of non-GAAP operating profit.
Last year, the company said non-GAAP revenue for the year to June 30, 2025 was up 9.8 percent to $US5,146,327,000, with non-GAAP net profit after tax up 19.3 percent to $1,763,300,000 (BD: Aug 1, 2025).
Today, Resmed said it expected the sale to close by October 2026, subject to required regulatory approvals and customary closing conditions and it intended to use the funds from the transaction to return capital to shareholders, including a share repurchase program, as well as for general corporate purposes.
The company said it expected to enter into a transition services agreement with Frazier Healthcare Partners to “facilitate continuity across systems, processes, tools, and day-to-day operations”.
Resmed said the sale reflected its “2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare”.
The company said the divestiture also strengthened its “ability to reallocate capital and resources toward innovation, operational scale and long-term value creation across its connected, home-based care ecosystem”.
Resmed executive chair Mick Farrell said by focusing on areas where the company saw “the greatest opportunity for sleep health innovation and impact, we are strengthening our ability to deliver life-changing health technologies, improve patient outcomes, and create value for our stakeholder”.
“We are confident Matrixcare and its affiliated businesses will continue to support team members and drive growth under new ownership with a dedicated focus on the long-term care market,” Mr Farrell said.
Resmed fell 25 cents or 0.8 percent to $31.19 with 1.6 million shares traded.

COGSTATE
Cogstate says net sales contracts executed for the year to June 30, 2026 were up 115.7 percent to $US89.0 million ($A128.2 million), compared to the prior year.
Cogstate said following the record year to June 30, 2026 in sales contracts for its central nervous system clinical trial measurement services and cognitive healthcare monitoring products it entered 2026-‘27 “with contracted future revenue of $US118.5 million, representing a 32 percent increase on the prior year”.
The company said it expected to recognize $US48.3 million as revenue in the year to June 30, 2027, “up 54 percent from the same time last year”.
Cogstate said contracted clinical trials revenue for the year to June 30, 2027 was $US46.1 million, up 58 percent from $US29.2 million at June 30, 2025, with contracted healthcare revenue flat year-to-year at $US2.3 million.
Cogstate fell 11 cents or 3.9 percent to $2.69.

[CURVEBEAM A.I.]
Curvebeam says it has “binding commitments” to raise $5 million at 2.0 cents a share in a non-underwritten placement, with a $1 million share plan at 1.8 cents a share to follow.
Curvebeam said the placement price was an 8.8 percent discount to the five-day volume weighted average price and an 11.1 percent discount to the last closing price of 1.8 cents.
The company said the placement included $300,000 from chief executive officer Greg Brown, with $2,050,000 from director Arun Singh, subject to shareholder approval, as well as $2,650,000 from other institutional investors.
Curvebeam said the funds would be used for sales and marketing expenses including preparing for China commercialization of its Hirise weight-bearing computed tomography (CT) device for musculo-skeletal conditions, research and development costs including product enhancement, supply chain costs and general working capital.
The company said Mr Singh agreed to advance a $2,050,000 unsecured loan at 5.0 percent annual interest, repayable on the earlier of October 1, 2027 or the day that Mr Singh subscribed for his $2,050,000 shares under the placement – “set off against his obligation to pay the subscription price for the new shares to the extent of the principal under the loan”.
Curvebeam said the $1 million, non-renounceable, non-underwritten share purchase plan had a record date of July 7, would open on July 29 and close on August 21, 2026.
Separately, in an Appendix 4C, the company said receipts from customers for the year to June 30, 2026 fell 36.0 percent to $7,784,000.
Curvebeam said receipts from the three months for its Hirise CT and related clinical assessment software was down 54.1 percent to $5,612,000, with a three-month cash burn of $2,429,000, leaving it with 0.67 quarters of cash.
The company said net cash outflows were expected to decrease as collections from customers increased and it received China National Medical Products Administration clearance for its Hirise system.
Curvebeam said the $5 million placement as well as $6 million in expected milestone payments from Wego Orthopaedics meant it expected “to be able to continue its operations and to meet its business objectives”.
Curvebeam was unchanged at 1.8 cents with 2.8 million shares traded.

[VITRAFY LIFE SCIENCES]
Vitrafy says it has raised $2.0 million at $2.60 in an “oversubscribed” share plan, with $9.4 million in valid applications received and taking the total raised to $32.0 million.
Last month, Vitrafy said that it had “firm commitments” to raise $30 million at $2.60 a share in an institutional placement, with a $2.0 million share purchase plan to follow (BD: Jun 12, 2026).
Today, the company said the board retained discretion regarding the allocation of the share purchase plan shares in the event that applications exceeded the amount sought to be raised and had exercised that discretion and determined to scale-back all valid applications on a pro-rata basis to limit dilution and provide an equitable allocation shares to shareholders.
Vitrafy said the funds would be used for the manufacture of its Guardion freezer devices to meet expected demand, US sales and operations as well as general working capital.
Separately, the company said that 21,185,051 shares would be released from voluntary escrow and available for trading on June 30, 2026.
Vitrafy fell five cents or 1.7 percent to $2.96.

THE UNIVERSITY OF NEWCASTLE

The University of Newcastle says it has developed a plasma bond allowing patches, burns or wound dressings and wearable sensors to stay in place longer and improve healing.
The New South Wales' University of Newcastle said that the development overcame a "longstanding limitation in current wound dressing, maintaining reliable, long-term adhesion with soft, tissue-like materials, without causing damage or discomfort, while withstanding moisture and movement" while it continued to deliver treatment and monitor healing.
The University said the current technology bonded soft hydrogels to stretchable polymer backings, but its plasma-based process "allowed wound dressings to remain in place for longer periods while enabling liquid treatments, such as anti-bacterial therapies to pass through the dressing", meaning that there were fewer dressing changes, less pain and improved healing.
The University of Newcastle said the hybrid device could "be stored in a dry form for years without degrading and can simply be rehydrated in a bio-molecule solution of choice when needed in the clinic".
The University said the device was toxin-free, produced using plasma processes which were environmentally friendly and opened "new possibility for how medical materials can function reliably on the body in real-world settings".
The University of Newcastle said laboratory testing conducted one week after injury showed the technology led to wound closure up-to 90 percent, while conventional dressings reached only 50 percent over the same period.
The University said a patent was pending in Australia and in other jurisdictions through the patent cooperation treaty process, with the technology to be adapted for advanced wound care, burn treatment, wearable health monitoring, soft robotics and artificial skin.

PROTEOMICS INTERNATIONAL LABORATORIES

Proteomics says the US Patent and Trademark Office has granted a patent for its Promarker Endo blood test for the diagnosis of endometriosis.
Proteomics said the patent, titled 'Endometriosis Biomarkers' would protect its intellectual property until March 2041, subject to grant and maintenance requirements.
The company said the patent covered methods of diagnosing endometriosis using specific protein biomarkers measured in blood samples, and using the results to guide treatment.
Proteomics was up half a cent or 3.2 percent to 16 cents with 2.4 million shares traded.

PYC THERAPEUTICS

PYC says the US Patent Office has granted composition of matter patents covering three drug candidates and extending the patent life for PYC-003, PYC-001 and VP-001.
PYC said the patents extended coverage for PYC-003 for polycystic kidney disease to June 13, 2044, PYC-001 for autosomal dominant optic atrophy until April 10, 2043 and VP-001 for retinitis pigmentosa type 11 to May 17, 2043.
The company had not responded to Biotech Daily questions regarding the titles of the patents at the time of publication.
PYC said patent claims for its PYC-002 drug candidate for Phelan-McDermid Syndrome were "yet to be examined".
PYC was up 2.5 cents or 1.6 percent to $1.56 with 1.3 million shares traded.

OPTHEA (TO BE CERYVYN THERAPEUTICS)

Opthea says its ‘Ceryvyn Therapeutics’ name change and ASX code ‘CYV’ have been approved, effective from tomorrow.
Last month, Opthea fell on its ASX relisting to develop OPT-302 for lymphangio-leio-myomatosis (LAM) and change its name and ticker code to ‘Ceryvyn Therapeutics’ and ‘CYV’, respectively (BD: Jun 3, 2026).
Last week, the company said its extraordinary general meeting had approved its change of name to ‘Ceryvyn’ with 99.65 percent in favor (BD: Jul 3, 2026).
Opthea fell 0.1 cents or 7.1 percent to 1.3 cents with 13.5 million shares traded.

PATRYS

Patrys director Leanne Kite says with Paralian Pty Ltd and Tyche Pty Ltd she has become a substantial holder in the company with 38,712,420 shares, or 5.75 percent.
Ms Kite said she bought 2,083,333 shares on July 3 for $50,000, or 2.4 cents a share.
Patrys was up 0.1 cents or 2.6 percent to 3.9 cents.

MICRO-X

Perennial Value Management says it has reduced its substantial shareholding in Micro-X from 57,013,436 shares (7.82%) to 50,799,251 shares (6.79%).
Sydney’s Perennial said it sold shares between June 2 and July 6, 2026, with the largest sale 1,551,205 shares on June 23 for $55,986, or 3.6 cents a share.
Micro-X fell 0.2 cents or 5.6 percent to 3.4 cents.

PRO MEDICUS

Pro Medicus says it has appointed Garry Sherriff as its head of investor relations, effective from July 20, 2026.
Pro Medicus said Mr Sherriff had more than 20 years of experience in equity research, investment banking, corporate finance, strategy, operations and management including as head of Australian emerging companies research at Moelis & Company (now MA Financial).
Pro Medicus was up $1.39 or 0.7 percent to $212.13 with 325,691 shares traded.